IL-10 (AM0010) phase I trial offers novel mechanism for immune-oncology drugs in solid tumors
More commonly known as an inhibitory cytokine, high doses of interleukin 10 (IL-10) have been shown to lead to the activation and survival of antigen...
Study: TruCulture & Gene Expression Characterizes Immune Responses
Published in the September 6, 2016 issue of Cell Reports, Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Indu...
DNA variants correlated with blood based biomarkers may predict disease features within COPD
By Sam LaBrie Developing precision medicines for COPD is an important goal, as the disease is the third most common cause of death in the developed...
Monitoring differences in the innate and adaptive immune response in Amish and Hutterite children
By Ralph McDade Let your kids get dirty; it’s good for them! In the current issue of the New England Journal of Medicine researchers explore the mec...
Researchers in this immuno-oncology trial used Myriad RBM’s services to measure serum biomarkers.
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma The data presented in this paper shows baseline and on-treatment biomarkers...
Impressions from Biomarkers and Diagnostics World Congress 2016
Our sales and marketing team represented Myriad RBM at the Biomarkers and Diagnostics World Congress in Philadelphia with a booth on the vendor floor....
Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia
An international team of researchers used Myriad RBM’s Multi-Analyte Profile (MAP) technology to identify a pattern of cardiometabolic biomarkers that...